IP Library › Granted Patent US 8,062,643
Granted Patent B2
US 8,062,643 · App. 11/925,938 · Granted Nov 22, 2011

Use of neurotoxin therapy for treatment of urologic and related disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,062,643
App. No.
11/925,938
Granted
Nov 22, 2011
Kind
B2
Abstract

The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

Claims (21)

1. A method for treating an urge type dysfunction in a patient, comprising administering a therapeutically effective amount of between 1.4 IU/kg to 17.1 IU/kg of botulinum toxin to a lateral bladder wall of the bladder of the patient, whereby the urge type dysfunction is treated.

2. The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

3. The method of claim 2 , wherein the botulinum toxin is botulinum toxin type A.

4. The method of claim 3 , wherein administration is to a bladder wall and administration is by single or serial injection.

5. The method of claim 3 , wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

6. The method of claim 3 , wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.

7. The method of claim 3 , wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A administered serially.

8. The method of claim 1 , wherein administration is by injection.

9. The method of claim 8 , wherein injection comprises a single injection.

10. The method of claim 8 , wherein injection comprises serial injection.

11. The method of claim 1 , wherein treating the urge type dysfunction provides the patient with sleep through the night that is uninterrupted by an urge to urinate.

12. The method of claim 1 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation.

13. A method for treating an urge type dysfunction in a patient, the method comprising administering, via injection, a therapeutically effective amount of between about 1.4 IU/kg and about 17.1 IU/kg of a botulinum toxin type A to a bladder of the patient, whereby the urge type dysfunction is treated.

14. The method of claim 13 , wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

15. The method of claim 13 , wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.

16. The method of claim 13 , wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A administered serially.

17. The method of claim 13 , wherein the therapeutically effective amount is provided as a single dose.

18. The method of claim 13 , wherein the therapeutically effective amount is provided as a divided dose.

19. The method of claim 13 , wherein frequency of urination during sleep is reduced.

20. The method of claim 13 , wherein the therapeutically effective amount is administered to a lateral wall of the bladder.

21. The method of claim 13 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: THE REGENTS OF THE UNIVERSITY OF COLORADO
To: ALLERGAN, INC.
Reel/Frame 036260/0570 →